Zavascki AP, Goldani LZ, Gonçalves AL et al (2007) High prevalence of metallo-beta-lactamase-mediated resistance challenging antimicrobial therapy against Pseudomonas aeruginosa in a Brazilian teaching hospital. Epidemiol Infect 135:343–345

Article  CAS  PubMed  Google Scholar 

Moya B, Barcelo IM, Bhagwat S et al (2017) Potent beta-Lactam enhancer activity of zidebactam and WCK 5153 against acinetobacter baumannii, including Carbapenemase-Producing clinical isolates. Antimicrob Agents Chemother; 61

Sader HS, Castanheira M, Huband M et al (2017) WCK 5222 (Cefepime-Zidebactam) antimicrobial activity against clinical isolates of Gram-Negative bacteria collected worldwide in 2015. Antimicrob Agents Chemother; 61

Moya B, Bhagwat S, Cabot G et al (2020) Effective Inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa. J Antimicrob Chemother 75:1474–1478

Article  CAS  PubMed  Google Scholar 

Moya B, Barcelo IM, Bhagwat S et al (2017) WCK 5107 (Zidebactam) and WCK 5153 are novel inhibitors of PBP2 showing potent beta-Lactam enhancer activity against Pseudomonas aeruginosa, including Multidrug-Resistant Metallo-beta-Lactamase-Producing High-Risk clones. Antimicrob Agents Chemother; 61

Hujer AM, Marshall SH, Mack AR et al (2023) Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through beta-lactam-enhancer-mechanism-based cefepime/zidebactam. mBio 14:e0111823

Article  PubMed  Google Scholar 

Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA (2024) Infectious diseases society of America 2024 guidance on the treatment of Antimicrobial-Resistant Gram-Negative infections. Clin Infect Dis ciae403. https://doi.org/10.1093/cid/ciae403

https://em100.edaptivedocs.net/partner/clsi/m100/CLSIInvestigationalUseOnlyBreakpoints2024.pdf

Winkler ML, Papp-Wallace KM, Hujer AM et al (2015) Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 59:1020–1029

Article  PubMed  PubMed Central  Google Scholar 

López M, Rojo-Bezares B, Chichón G et al (2022) Resistance to fluoroquinolones in Pseudomonas aeruginosa from human, animal, food and environmental origin: the role of CrpP and mobilizable ICEs. Antibiot (Basel Switzerland); 11

Jean SS, Lee WS, Lam C et al (2015) Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options. Future Microbiol 10:407–425

Article  CAS  PubMed  Google Scholar 

Bissantz C, Zampaloni C, David-Pierson P et al (2024) Translational PK/PD for the Development of Novel Antibiotics-A Drug Developer’s Perspective. Antibiot (Basel Switzerland); 13

Moore JN, Poon L, Pahwa S et al (2023) Animal pharmacokinetics/pharmacodynamics (PK/PD) infection models for clinical development of antibacterial drugs: lessons from selected cases. J Antimicrob Chemother 78:1337–1343

Article  PubMed  Google Scholar 

Kidd JM, Abdelraouf K, Nicolau DP (2020) Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model. J Antimicrob Chemother 75:149–155

CAS  PubMed  Google Scholar 

Monogue ML, Tabor-Rennie J, Abdelraouf K et al (2019) In vivo efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the neutropenic murine thigh infection model. Antimicrob Agents Chemother; 63

Huband MD, Castanheira M, Jones RN, Rhomberg PR, Watters AA, Sader HS WCK 5222 (Cefepime-Zidebactam) In Vitro Time-kill Studies against Pseudomonas aeruginosa and Acinetobacter baumannii Isolates with Characterized β-lactamases. ASM MICROBE 2016, Friday-477, Boston, MA, June 16–20

Barcelo I, Cabot G, Palwe S et al (2021) In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy. J Antimicrob Chemother 76:2546–2557

Article  CAS  PubMed  Google Scholar 

Karlowsky JA, Walkty AJ, Baxter MR et al (2022) In vitro activity of Cefiderocol against extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019. Microbiol Spectr 10:e0172422

Article  PubMed  Google Scholar 

Malisova L, Vrbova I, Pomorska K et al (2023) In vitro activity of Cefiderocol against Carbapenem-Resistant enterobacterales and Pseudomonas aeruginosa. Microb Drug Resist (Larchmont NY) 29:485–491

Article  CAS  Google Scholar 

Simner PJ, Palavecino EL, Satlin MJ et al (2023) Potential of inaccurate Cefiderocol susceptibility results: a CLSI AST subcommittee advisory. J Clin Microbiol 61:e0160022

Article  PubMed  Google Scholar 

Katsube T, Nicolau DP, Rodvold KA et al (2021) Intrapulmonary Pharmacokinetic profile of Cefiderocol in mechanically ventilated patients with pneumonia. J Antimicrob Chemother 76:2902–2905

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mushtaq S, Sadouki Z, Vickers A et al (2020) In vitro activity of cefiderocol, a siderophore cephalosporin, against Multidrug-Resistant Gram-Negative bacteria. Antimicrob Agents Chemother; 64

Karakonstantis S, Rousaki M, Kritsotakis EI, Cefiderocol (2022) Systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. Antibiot (Basel Switzerland); 11

Soman R, Sirsat R, Sunavala A et al (2024) Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by new Delhi metallo-beta-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime/zidebactam (WCK 5222). Eur J Clin Microbiol Infect Dis